Company profile: HilleVax
1.1 - Company Overview
Company description
- Provider of novel vaccine development and commercialization, focused on HIL-214, a bivalent GI.1/GII.4 virus-like particle (VLP) vaccine candidate in development to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection.
Products and services
- Commercialization of Novel Vaccines: Executes commercialization of novel vaccines, delivering biopharmaceutical products to market following development activities within the company
- Development of Novel Vaccines: Develops and architects novel vaccines, advancing biopharmaceutical vaccine candidates from concept through development activities within the company
- HIL-214: A bivalent GI.1/GII.4 VLP-based vaccine candidate in development to prevent moderate-to-severe acute gastroenteritis from norovirus infection, combining GI.1 and GII.4 virus-like particles
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HilleVax
OM Pharma
HQ: Switzerland
Website
- Description: Provider of microbial-derived immunotherapeutic products addressing acute and chronic immunological disorders from infections and inflammation, operating worldwide through partners and investing in R&D. Products include Broncho-Vaxom to regulate the immune system and prevent recurrent respiratory infections, Uro-Vaxom to treat and prevent recurrent lower urinary tract infections, and Dicynone for capillary hemorrhage prevention and treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OM Pharma company profile →
IncellDx
HQ: United States
Website
- Description: Provider of molecular diagnostics focused on detecting and monitoring life-threatening viral diseases, offering HPV OncoTect 3Dx assay quantifying E6/E7 mRNA for cervical cancer; incellKINE Long COVID in vitro diagnostic (CE marked); HPV E6/E7 mRNA probe; CMV mRNA probe (RUO); hybridization core reagents; and HPV control cells (RUO).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IncellDx company profile →
Alpha-Tec Systems
HQ: United States
Website
- Description: Provider of accurate specimen collection, transportation, processing, and quality control solutions for clinical labs, including AFB processing systems (NAC-PAC EA3, UNITARY, RED), fertility and immune testing products (QC-Beads, CitricScreen, FructoScreen, LeucoScreen, ImmunoSpheres, MarScreen), Microbix REDx and PROCEEDx controls, and the OxA oxalic acid decontamination kit for Pseudomonas spp.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpha-Tec Systems company profile →
Stat-Sure Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic testing specializing in HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Sure Diagnostics company profile →
ContraFect
HQ: United States
Website
- Description: Provider of biotechnology research focused on monoclonal antibodies to treat life-threatening infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ContraFect company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HilleVax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HilleVax
2.2 - Growth funds investing in similar companies to HilleVax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HilleVax
4.2 - Public trading comparable groups for HilleVax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →